公开(公告)号：US20100125069A1

公开(公告)日：2010-05-20

申请号：US12691657

申请日：2010-01-21

申请人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

发明人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

IPC分类号： A61K31/5365 ,  C07D265/36 ,  A61P37/06

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04 ,  Y10S514/825 ,  Y10S514/903

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

摘要翻译： 本发明提供了用2,4-嘧啶二胺化合物治疗或预防自身免疫疾病的方法，以及治疗，预防或改善与这些疾病相关的症状的方法。 可以用化合物治疗或预防的自身免疫性疾病的具体实例包括类风湿性关节炎和/或其相关症状，系统性红斑狼疮病和/或其相关症状和多发性硬化症和/或其相关症状。

公开(公告)号：US08557806B2

公开(公告)日：2013-10-15

申请号：US13418696

申请日：2012-03-13

申请人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

发明人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

IPC分类号： A61K31/5383

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04 ,  Y10S514/825 ,  Y10S514/903

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

公开(公告)号：US07655797B2

公开(公告)日：2010-02-02

申请号：US12199705

申请日：2008-08-27

申请人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Susan Molineaux ,  Sacha J. Holland ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li ,  Alexander B Rossi

发明人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Susan Molineaux ,  Sacha J. Holland ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li ,  Alexander B Rossi

IPC分类号： C07D239/02

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5395 ,  A61K31/551 ,  A61K45/06 ,  C07D239/48 ,  C07D265/36 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D498/04 ,  C07D498/14 ,  C07F5/027

摘要： The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. Certain disclosed embodiments concern contacting compounds having a formula or a salt or N-oxide thereof, with 2,4-dichloro-5-fluoropyrimidine under conditions to provide compounds having a formula

摘要翻译： 本发明提供了抑制导致释放化学介质，中间体和合成化合物的方法的IgE和/或IgG受体信号级联的2,4-嘧啶二胺化合物和在多种情况下使用化合物的方法，包括 在治疗和预防以IgE和/或IgG受体信号传导级联的活化作用通过脱颗粒和其它方法释放化学介质引起或与之相关的疾病。 某些公开的实施方案涉及将具有式的化合物或其盐或N-氧化物与2,4-二氯-5-氟嘧啶接触的条件下，提供具有式

公开(公告)号：US20120230984A1

公开(公告)日：2012-09-13

申请号：US13418696

申请日：2012-03-13

申请人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

发明人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

IPC分类号： A61K31/506 ,  A61K31/5383 ,  A61K31/56 ,  A61K31/616 ,  A61K31/519 ,  A61P37/06 ,  A61P37/08 ,  A61K39/395 ,  A61P7/06 ,  A61P25/00 ,  A61P7/00 ,  A61P27/02 ,  A61P21/04 ,  A61P1/16 ,  A61P13/12 ,  A61P29/00 ,  A61P19/02 ,  A61P19/04 ,  A61K31/538

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04 ,  Y10S514/825 ,  Y10S514/903

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

摘要翻译： 本发明提供了用2,4-嘧啶二胺化合物治疗或预防自身免疫疾病的方法，以及治疗，预防或改善与这些疾病相关的症状的方法。 可以用化合物治疗或预防的自身免疫性疾病的具体实例包括类风湿性关节炎和/或其相关症状，系统性红斑狼疮病和/或其相关症状和多发性硬化症和/或其相关症状。

公开(公告)号：US07825116B2

公开(公告)日：2010-11-02

申请号：US11539101

申请日：2006-10-05

申请人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

发明人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

IPC分类号： C07D239/48 ,  C07D403/12 ,  A61K31/506

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04 ,  Y10S514/825 ,  Y10S514/903

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

摘要翻译： 本发明提供了用2,4-嘧啶二胺化合物治疗或预防自身免疫疾病的方法，以及治疗，预防或改善与这些疾病相关的症状的方法。 可以用化合物治疗或预防的自身免疫性疾病的具体实例包括类风湿性关节炎和/或其相关症状，系统性红斑狼疮病和/或其相关症状和多发性硬化症和/或其相关症状。

公开(公告)号：US07812029B1

公开(公告)日：2010-10-12

申请号：US12028581

申请日：2008-02-08

申请人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

发明人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

IPC分类号： C07D239/42

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04 ,  Y10S514/825 ,  Y10S514/903

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

摘要翻译： 本发明提供了用2,4-嘧啶二胺化合物治疗或预防自身免疫疾病的方法，以及治疗，预防或改善与这些疾病相关的症状的方法。 可以用化合物治疗或预防的自身免疫性疾病的具体实例包括类风湿性关节炎和/或其相关症状，系统性红斑狼疮病和/或其相关症状和多发性硬化症和/或其相关症状。

公开(公告)号：US08148525B2

公开(公告)日：2012-04-03

申请号：US12762178

申请日：2010-04-16

申请人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Susan Molineaux ,  Sasha J. Holland ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li ,  Alexander B. Rossi

发明人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Susan Molineaux ,  Sasha J. Holland ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li ,  Alexander B. Rossi

IPC分类号： C07D239/48

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5395 ,  A61K31/551 ,  A61K45/06 ,  C07D239/48 ,  C07D265/36 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D498/04 ,  C07D498/14 ,  C07F5/027

摘要： The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

公开(公告)号：US07517886B2

公开(公告)日：2009-04-14

申请号：US10631029

申请日：2003-07-29

申请人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

发明人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

IPC分类号： A61K31/4965

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04 ,  Y10S514/825 ,  Y10S514/903

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

公开(公告)号：US20090171085A1

公开(公告)日：2009-07-02

申请号：US12268235

申请日：2008-11-10

申请人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Susan Molineaux ,  Sacha J. Holland ,  Jeffrey Clough ,  Holger Keim ,  Someasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li ,  Alexander B. Rossi

发明人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Susan Molineaux ,  Sacha J. Holland ,  Jeffrey Clough ,  Holger Keim ,  Someasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li ,  Alexander B. Rossi

IPC分类号： C07D239/48

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5395 ,  A61K31/551 ,  A61K45/06 ,  C07D239/48 ,  C07D265/36 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D498/04 ,  C07D498/14 ,  C07F5/027

摘要： The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

公开(公告)号：US20120245127A1

公开(公告)日：2012-09-27

申请号：US13487979

申请日：2012-06-04

申请人： Esteban Masuda ,  Donald G. Payan ,  Elliot B. Grossbard ,  Somasekhar Bhamidipati ,  Rajinder Singh

发明人： Esteban Masuda ,  Donald G. Payan ,  Elliot B. Grossbard ,  Somasekhar Bhamidipati ,  Rajinder Singh

IPC分类号： A61K31/5383 ,  A61P35/02 ,  A61K31/505 ,  A61P35/00 ,  A61K31/675 ,  A61K31/5415

CPC分类号： A61K31/505 ,  A61K31/5383 ,  A61K31/542

摘要： The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a Syk kinase or Syk/Flt-3 kinase inhibitor. Cell proliferative disorders treatable by the methods include, hematopoietic neoplasms and virally associated tumors. The compounds are also directed to therapeutic or prophylactic inhibition of tumor metastasis.

摘要翻译： 本公开提供了通过施用Syk激酶或Syk / Flt-3激酶抑制剂治疗细胞增殖性疾病的方法。 可通过该方法治疗的细胞增殖性疾病包括造血赘生物和病毒相关的肿瘤。 该化合物还涉及肿瘤转移的治疗或预防性抑制。